Evidence map›Paper›PMID 25000405›Full record

ArticlePloS one2014

Effects of candesartan on electrical remodeling in the hearts of inherited dilated cardiomyopathy model mice.

Fuminori Odagiri, Hana Inoue, Masami Sugihara, Takeshi Suzuki, Takashi Murayama, Takao Shioya, Masato Konishi, Yuji Nakazato, Hiroyuki Daida, Takashi Sakurai and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. KCells · 2023
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Fuminori OdagiriDepartment of Cellular and Molecular Pharmacology, Juntendo University Graduate School of Medicine, Tokyo, Japan; Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Hana InoueDepartment of Physiology, Tokyo Medical University, Tokyo, Japan.
Masami SugiharaDepartment of Cellular and Molecular Pharmacology, Juntendo University Graduate School of Medicine, Tokyo, Japan; Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Takeshi SuzukiDepartment of Cellular and Molecular Pharmacology, Juntendo University Graduate School of Medicine, Tokyo, Japan; Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Takashi MurayamaDepartment of Cellular and Molecular Pharmacology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Takao ShioyaDepartment of Physiology, Faculty of Medicine, Saga University, Saga, Japan.
Masato KonishiDepartment of Physiology, Tokyo Medical University, Tokyo, Japan.
Yuji NakazatoDepartment of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Hiroyuki DaidaDepartment of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Takashi SakuraiDepartment of Cellular and Molecular Pharmacology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Sachio MorimotoDepartment of Clinical Pharmacology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Nagomi KurebayashiDepartment of Cellular and Molecular Pharmacology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Juntendo University · JPTokyo Medical University · JPKyushu University · JPSaga University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inherited dilated cardiomyopathy (DCM) is characterized by dilatation and dysfunction of the ventricles, and often results in sudden death or heart failure (HF). Although angiotensin receptor blockers (ARBs) have been used for the treatment of HF, little is known about the effects on postulated electrical remodeling that occurs in inherited DCM. The aim of this study was to examine the effects of candesartan, one of the ARBs, on cardiac function and electrical remodeling in the hearts of inherited DCM model mice (TNNT2 ΔK210). DCM mice were treated with candesartan in drinking water for 2 months from 1 month of age. Control, non-treated DCM mice showed an enlargement of the heart with prolongation of QRS and QT intervals, and died at t1/2 of 70 days. Candesartan dramatically extended the lifespan of DCM mice, suppressed cardiac dilatation, and improved the functional parameters of the myocardium. It also greatly suppressed prolongation of QRS and QT intervals and action potential duration (APD) in the left ventricular myocardium and occurrence of ventricular arrhythmia. Expression analysis revealed that down-regulation of Kv4.2 (Ito channel protein), KChIP2 (auxiliary subunit of Kv4.2), and Kv1.5 (IKur channel protein) in DCM was partially reversed by candesartan administration. Interestingly, non-treated DCM heart had both normal-sized myocytes with moderately decreased Ito and IKur and enlarged cells with greatly reduced K+ currents (Ito, IKur IK1 and Iss). Treatment with candesartan completely abrogated the emergence of the enlarged cells but did not reverse the Ito, and IKur in normal-sized cells in DCM hearts. Our results indicate that candesartan treatment suppresses structural remodeling to prevent severe electrical remodeling in inherited DCM.

Indexed as

Angiotensin Receptor AntagonistsAnimalsAtrial RemodelingBenzimidazolesBiphenyl CompoundsCardiomyopathy, DilatedDisease Models, AnimalElectrocardiographyElectrophysiological PhenomenaGene Expression RegulationGene Knock-In TechniquesHeartHeart VentriclesMiceMice, Inbred C57BLMyocytes, CardiacAngiotensin Receptor AntagonistsBenzimidazolesBiphenyl CompoundscandesartanPotassiumPotassium ChannelsTetrazoles

Identifiers

PMID25000405
PMCPMC4084897
OpenAlexW2090937873

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.